Olga Milena García Morales
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Olga Milena García Morales has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Andrés Celis Preciado
Faculté de Médecine et des Sciences de la Santé Université de Sherbrooke Sherbrooke Québec Canada
6 shared publications - Claudio Villaquirán Torres
Hospital Universitario San Ignacio
3 shared publications - Juan José Yepes-Nuñez
School of Medicine, Universidad de los Andes, Bogota, Colombia
3 shared publications - Alejandra Cañas
Departamento de Medicina Interna, School of Medicine, Pontificia Universidad Javeriana, Carrera 7 No. 40-62, 2.Ed. Fernando Barón, Bogotá 110231, Colombia
2 shared publications - Ivan Dario Florez
Department of Pediatrics, University of Antioquia, Medellin, Colombia
2 shared publications - Ivan Solarte
University Hospital Fundación Santafé de Bogotá, Internal Medicine-Pulmonary Department
2 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by Sociedad Colombiana de Anestesiologia y Reanimacion (SCARE) in Colombian Journal of Anesthesiology
GRADE 1 approach in Spanish: Introduction to the GRADE framework
Introduction: The GRADE (Grading of Recommendations Assessment Development and Evaluation) working group brings together engaged professionals to develop an optimal system for assessing the certainty of the evidence derived from systematic reviews, as well as for health care technologies, and to determine the strength of clinical practice guideline recommendations. Objective: This article provides an introduction to the GRADE approach and to the evidence profile and summary of findings tables for presenting evidence certainty (quality or confidence) ratings. These tables can be used in the context of systematic reviews as well as in health care technology assessments and clinical practice guidelines covering different options for treatment, diagnosis, values and preferences, among others. Methodology: The GRADE process begins with a question which specifies all the outcomes that are important to the patient. After gathering and summarizing the evidence for each outcome, GRADE offers explicit domains to rate the certainty of the evidence, including study limitations, imprecision, inconsistency, indirectness and publication bias. Results: The certainty of the evidence for each outcome is rated as high, moderate, low or very low. In the case of recommendations, these are classified as strong or conditional (formerly weak), and in favor or against. Evidence profile tables are used to report the assessment of each of the GRADE domains as well the certainty ratings for every outcome. Summary of findings tables report the final result of the certainty evaluation process for each outcome. Conclusions: GRADE recommends assessing the certainty of the evidence for each outcome that is important to the patient and presenting this assessment succinctly in transparent and informative evidence tables.
- 15 May 2026
- Published by Sociedad Colombiana de Anestesiologia y Reanimacion (SCARE) in Colombian Journal of Anesthesiology
Open AccessGRADE 1 approach in Spanish: Introduction to the GRADE framework
Introduction: The GRADE (Grading of Recommendations Assessment Development and Evaluation) working group brings together engaged professionals to develop an optimal system for assessing the certainty of the evidence derived from systematic reviews, as well as for health care technologies, and to determine the strength of clinical practice guideline recommendations. Objective: This article provides an introduction to the GRADE approach and to the evidence profile and summary of findings tables for presenting evidence certainty (quality or confidence) ratings. These tables can be used in the context of systematic reviews as well as in health care technology assessments and clinical practice guidelines covering different options for treatment, diagnosis, values and preferences, among others. Methodology: The GRADE process begins with a question which specifies all the outcomes that are important to the patient. After gathering and summarizing the evidence for each outcome, GRADE offers explicit domains to rate the certainty of the evidence, including study limitations, imprecision, inconsistency, indirectness and publication bias. Results: The certainty of the evidence for each outcome is rated as high, moderate, low or very low. In the case of recommendations, these are classified as strong or conditional (formerly weak), and in favor or against. Evidence profile tables are used to report the assessment of each of the GRADE domains as well the certainty ratings for every outcome. Summary of findings tables report the final result of the certainty evaluation process for each outcome. Conclusions: GRADE recommends assessing the certainty of the evidence for each outcome that is important to the patient and presenting this assessment succinctly in transparent and informative evidence tables.
- 12 April 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 256, 108815
Biological therapy for chronic obstructive pulmonary disease (COPD): Effectiveness and safety
- 12 April 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 256, 108815
Biological therapy for chronic obstructive pulmonary disease (COPD): Effectiveness and safety
- Top Cited PapersOpen Access
- 1 January 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-13
Beyond Reported Rates: Detection-Adjusted COPD Prevalence and Underdiagnosis Patterns in Colombia
Background: Chronic obstructive pulmonary disease (COPD) is widely underdiagnosed in Colombia, especially in rural departments with limited access to spirometry. We conducted a department-level ecological study using aggregated administrative data from 2020– 2023 to generate diagnosis-based COPD prevalence estimates that explicitly account for regional disparities in diagnostic capacity and socioeconomic conditions. Methods: We assembled department-year data from the Individual Registry of Health Services Delivery, national mortality statistics, and the National Quality of Life Survey. A Bayesian generalized additive model with a Gamma family and log link was fitted to a Composite Bias-Correction Multiplier that captured under-ascertainment as a function of spirometry utilization, COPD lethality, outpatient contact rates, multidimensional poverty, household fuel type, and age structure. Posterior estimates of this multiplier were applied to diagnosis-based COPD prevalence in adults aged ≥ 40 years to obtain detection-adjusted departmental and national estimates. Model performance was summarized using the Bayesian R2 (proportion of variability in the multiplier explained by the covariates) and the leave-one-out information criterion (LOOIC) as a measure of expected predictive fit. Results: The model estimated a population-weighted national COPD prevalence of 2.22% (95% credible interval [CrI], 2.21– 2.23). Detection-adjusted departmental prevalence ranged from 0.81% in Vichada to 3.50% in Caldas, whereas diagnosis-based prevalence ranged from 0.27% to 2.22%. Spirometry utilization correlated strongly with diagnosis-based prevalence (r = 0.85, p < 0.001), and departments with higher COPD lethality and greater multidimensional poverty required larger adjustment multipliers. The model explained most of the variability in the Composite Bias-Correction Multiplier (Bayesian R2 = 0.99) and showed good expected predictive performance (LOOIC = – 461.1). Conclusion: COPD prevalence in Colombia shows marked regional heterogeneity driven by demographic risk and uneven diagnostic capacity. Detection-adjusted estimates indicate that the highest burden lies in Andean departments such as Caldas, Boyacá, and Risaralda, while remote Amazon and Orinoco territories experience substantial underdiagnosis. These findings support targeted expansion of spirometry and chronic respiratory care in underserved regions and illustrate how accounting for detection bias can improve chronic disease surveillance in low- and middle-income settings. Plain Language Summary: Why was this study done? Chronic Obstructive Pulmonary Disease (COPD) is a serious lung condition that makes breathing difficult. In Colombia, many people with COPD are not properly diagnosed, especially in rural areas where healthcare services are limited. Previous studies estimating how many people have COPD in Colombia may not be accurate because they did not consider these differences in healthcare access between regions. What did the researchers do and find? We studied COPD rates across all 33 departments (states) in Colombia using advanced statistical methods. We looked at factors such as how often spirometry tests are performed, poverty levels, and access to modern cooking stoves. We estimated that 2.22% of Colombians have COPD (95% credible interval [CrI]: 2.21– 2.23%), but this varies widely between regions—from 0.81% to 3.50%. Areas with better access to spirometry, a breathing test used to confirm COPD, showed higher diagnosis rates, which suggests that many cases are missed where testing capacity is limited. What do these results mean? These results indicate that diagnosis-based COPD prevalence during 2020– 2023 is lower than historical spirometry-based estimates, likely reflecting under-ascertainment in places where spirometry access is limited. None of Colombia’s 33 departments reaches the National Administrative Benchmark of 1105 spirometry tests per 100,000 adults aged ≥ 40 years, and only Bogotá approaches half of this target. This information can guide health authorities to expand lung function testing and chronic respiratory care in underserved regions. The same modeling strategy could be applied to other chronic diseases that are underdiagnosed in low-resource settings.
- 1 January 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-13
Top Cited PapersOpen AccessBeyond Reported Rates: Detection-Adjusted COPD Prevalence and Underdiagnosis Patterns in Colombia
Background: Chronic obstructive pulmonary disease (COPD) is widely underdiagnosed in Colombia, especially in rural departments with limited access to spirometry. We conducted a department-level ecological study using aggregated administrative data from 2020– 2023 to generate diagnosis-based COPD prevalence estimates that explicitly account for regional disparities in diagnostic capacity and socioeconomic conditions. Methods: We assembled department-year data from the Individual Registry of Health Services Delivery, national mortality statistics, and the National Quality of Life Survey. A Bayesian generalized additive model with a Gamma family and log link was fitted to a Composite Bias-Correction Multiplier that captured under-ascertainment as a function of spirometry utilization, COPD lethality, outpatient contact rates, multidimensional poverty, household fuel type, and age structure. Posterior estimates of this multiplier were applied to diagnosis-based COPD prevalence in adults aged ≥ 40 years to obtain detection-adjusted departmental and national estimates. Model performance was summarized using the Bayesian R2 (proportion of variability in the multiplier explained by the covariates) and the leave-one-out information criterion (LOOIC) as a measure of expected predictive fit. Results: The model estimated a population-weighted national COPD prevalence of 2.22% (95% credible interval [CrI], 2.21– 2.23). Detection-adjusted departmental prevalence ranged from 0.81% in Vichada to 3.50% in Caldas, whereas diagnosis-based prevalence ranged from 0.27% to 2.22%. Spirometry utilization correlated strongly with diagnosis-based prevalence (r = 0.85, p < 0.001), and departments with higher COPD lethality and greater multidimensional poverty required larger adjustment multipliers. The model explained most of the variability in the Composite Bias-Correction Multiplier (Bayesian R2 = 0.99) and showed good expected predictive performance (LOOIC = – 461.1). Conclusion: COPD prevalence in Colombia shows marked regional heterogeneity driven by demographic risk and uneven diagnostic capacity. Detection-adjusted estimates indicate that the highest burden lies in Andean departments such as Caldas, Boyacá, and Risaralda, while remote Amazon and Orinoco territories experience substantial underdiagnosis. These findings support targeted expansion of spirometry and chronic respiratory care in underserved regions and illustrate how accounting for detection bias can improve chronic disease surveillance in low- and middle-income settings. Plain Language Summary: Why was this study done? Chronic Obstructive Pulmonary Disease (COPD) is a serious lung condition that makes breathing difficult. In Colombia, many people with COPD are not properly diagnosed, especially in rural areas where healthcare services are limited. Previous studies estimating how many people have COPD in Colombia may not be accurate because they did not consider these differences in healthcare access between regions. What did the researchers do and find? We studied COPD rates across all 33 departments (states) in Colombia using advanced statistical methods. We looked at factors such as how often spirometry tests are performed, poverty levels, and access to modern cooking stoves. We estimated that 2.22% of Colombians have COPD (95% credible interval [CrI]: 2.21– 2.23%), but this varies widely between regions—from 0.81% to 3.50%. Areas with better access to spirometry, a breathing test used to confirm COPD, showed higher diagnosis rates, which suggests that many cases are missed where testing capacity is limited. What do these results mean? These results indicate that diagnosis-based COPD prevalence during 2020– 2023 is lower than historical spirometry-based estimates, likely reflecting under-ascertainment in places where spirometry access is limited. None of Colombia’s 33 departments reaches the National Administrative Benchmark of 1105 spirometry tests per 100,000 adults aged ≥ 40 years, and only Bogotá approaches half of this target. This information can guide health authorities to expand lung function testing and chronic respiratory care in underserved regions. The same modeling strategy could be applied to other chronic diseases that are underdiagnosed in low-resource settings.
- Open Access
Biological Therapy for Chronic Obstructive Pulmonary Disease (COPD): Efficacy and Safety
Background: The predominant airway inflammation in chronic obstructive pulmonary disease (COPD) is neutrophilic, although numerous studies have shown that eosinophilic inflammation contributes significantly to COPD. Eosinophilic COPD patients are characterized by a greater number of total exacerbations and higher hospitalization rates. Biological therapy targets multiple steps in eosinophilic inflammation, providing a promising approach to reduce exacerbation frequency and mortality. Objective: To provide a timely, rigorous, and continuously updated summary of the evidence available on the role of biological therapy for the treatment of patients with COPD. Design: This is a Living Evidence synthesis, that starts with a baseline synthesis report of the effects of the intervention on the main predefined outcomes. Based on its conclusions, we will set up the living evidence approach, and the evidence monitoring will begin. Methods: Evidence identification, screening, and selection: Automated living searches were performed in relevant databases following the Epistemonikos procedures. Results were incorporated into the Epistemonikos “Living OVerview of Evidence (L.OVE)” platform which was used for evidence screening, and selection. Two reviewers screened all titles and abstracts supported by the platform automated classifiers that excluded references with a low probability of being relevant. For this baseline report we included randomized trials that evaluated the use of biological therapy compared to the use of standard-of-therapy alone in adult patients with COPD. Main outcomes defined as critical or important for decision making include exacerbation rate, exacerbation-free time, lung function and quality of life. Two reviewers independently screened each study for eligibility, extract data, and assess its methodological quality using appropriate tools. We performed meta-analyses of the study’s results when pertinent. We applied the GRADE approach to assess the certainty of the evidence found for each outcome. We will continuously monitor the evidence by performing daily searches and monthly screening of the retrieved references. Additionally, each three months we will manually search for ongoing studies in the International Clinical Trials Registry Platform trial registries. The evidence monitoring, including decisions to incorporate evidence and withdraw the question from the living mode will follow the process proposed by the Living Evidence to Inform Health Decisions framework (ref) as stated in our protocol. A living, web-based version of this review will be openly available during the next year at https://livingevidenceihd.com/lesrepo/ . We will resubmit it every time the conclusions change or whenever there are substantial updates. Results: Initial searches retrieved 24 systematic reviews, 2 evaluating the use of biologics on COPD, which included 6 randomized control trials. Additional searches retrieved 125 randomized controlled trials (RCTs). Of these, 31 RCTs were deemed potentially eligible and were reviewed in full text. Ultimately, 9 RCTs evaluating the use of biological therapies (MEDI8968, benralizumab, mepolizumab, dupilumab, astegolimab, and itepekimab) compared to placebo in COPD patients were included. The GRADE quality of evidence for the main outcomes was assessed as intermediate. Conclusions: The evidence suggests that biological therapies may reduce the risk of exacerbations in patients with chronic obstructive pulmonary disease (COPD). However, the overall impact on lung function and quality of life remains inconclusive. The variability in study outcomes, particularly concerning SGRQ scores and FEV1, emphasizes the need for continuing monitoring evidence. PROSPERO /OSF Protocol Registration DOI: 10.17605/OSF.IO/SUYD2 STRUCTURED Objective: To synthesize and update evidence on the efficacy and safety of biological therapy for chronic obstructive pulmonary disease (COPD). Methods: This living evidence synthesis included systematic reviews (SRs) and randomized controlled trials (RCTs) comparing biological therapies (e.g., benralizumab, mepolizumab, dupilumab) with placebo or standard care in adults with moderate to severe COPD. Automated searches were conducted using the Epistemonikos “Living Overview of Evidence” (L.OVE) platform, supplemented by manual searches. Two reviewers independently screened studies, extracted data, and assessed risk of bias using Cochrane RoB2 for RCTs and AMSTAR II for SRs. Meta-analyses were performed, and the certainty of evidence was evaluated using the GRADE approach. Results: Nine RCTs were included. Biological therapy probably reduces annual exacerbation rates (moderate certainty; MD -0.12, 95% CI -0.23 to 0.00). The evidence is very uncertain about its effect on quality of life (SGRQ score: MD 0.05, 95% CI -0.04 to 0.14; very low certainty) due to serious inconsistency (I² = 95.5%) and imprecision. Biological therapy may result in little to no difference in lung function (FEV1: MD 0.02, 95% CI -0.02 to 0.06; low certainty), with serious inconsistency (I² = 76.8%) and imprecision. Biological therapy probably results in no difference in total adverse events (moderate certainty; RR 1.02, 95% CI 0.99 to 1.05) but likely reduces severe adverse events (high certainty; RR 0.84, 95% CI 0.77 to 0.93). Conclusions: Current evidence suggests that biological therapies for COPD provide little to no clinical benefit over standard care in terms of exacerbation rates, lung function, or safety, with uncertain effects on quality of life. Biological therapy probably has little to no effect on annual exacerbations compared with standard care. There is likely no meaningful difference in lung function (FEV1) compared with standard care. Biologicals probably result in no difference in the number of total adverse events. Regarding the effect on quality of life, measured by the SGRQ compared with standard care, the evidence is very uncertain; therefore, no conclusions can be drawn. Overall, the certainty of the evidence supporting these statements is generally moderate, but is particularly limited by imprecision in estimates when considering thresholds for the minimal important difference (MID).
Open AccessBiological Therapy for Chronic Obstructive Pulmonary Disease (COPD): Efficacy and Safety
Background: The predominant airway inflammation in chronic obstructive pulmonary disease (COPD) is neutrophilic, although numerous studies have shown that eosinophilic inflammation contributes significantly to COPD. Eosinophilic COPD patients are characterized by a greater number of total exacerbations and higher hospitalization rates. Biological therapy targets multiple steps in eosinophilic inflammation, providing a promising approach to reduce exacerbation frequency and mortality. Objective: To provide a timely, rigorous, and continuously updated summary of the evidence available on the role of biological therapy for the treatment of patients with COPD. Design: This is a Living Evidence synthesis, that starts with a baseline synthesis report of the effects of the intervention on the main predefined outcomes. Based on its conclusions, we will set up the living evidence approach, and the evidence monitoring will begin. Methods: Evidence identification, screening, and selection: Automated living searches were performed in relevant databases following the Epistemonikos procedures. Results were incorporated into the Epistemonikos “Living OVerview of Evidence (L.OVE)” platform which was used for evidence screening, and selection. Two reviewers screened all titles and abstracts supported by the platform automated classifiers that excluded references with a low probability of being relevant. For this baseline report we included randomized trials that evaluated the use of biological therapy compared to the use of standard-of-therapy alone in adult patients with COPD. Main outcomes defined as critical or important for decision making include exacerbation rate, exacerbation-free time, lung function and quality of life. Two reviewers independently screened each study for eligibility, extract data, and assess its methodological quality using appropriate tools. We performed meta-analyses of the study’s results when pertinent. We applied the GRADE approach to assess the certainty of the evidence found for each outcome. We will continuously monitor the evidence by performing daily searches and monthly screening of the retrieved references. Additionally, each three months we will manually search for ongoing studies in the International Clinical Trials Registry Platform trial registries. The evidence monitoring, including decisions to incorporate evidence and withdraw the question from the living mode will follow the process proposed by the Living Evidence to Inform Health Decisions framework (ref) as stated in our protocol. A living, web-based version of this review will be openly available during the next year at https://livingevidenceihd.com/lesrepo/ . We will resubmit it every time the conclusions change or whenever there are substantial updates. Results: Initial searches retrieved 24 systematic reviews, 2 evaluating the use of biologics on COPD, which included 6 randomized control trials. Additional searches retrieved 125 randomized controlled trials (RCTs). Of these, 31 RCTs were deemed potentially eligible and were reviewed in full text. Ultimately, 9 RCTs evaluating the use of biological therapies (MEDI8968, benralizumab, mepolizumab, dupilumab, astegolimab, and itepekimab) compared to placebo in COPD patients were included. The GRADE quality of evidence for the main outcomes was assessed as intermediate. Conclusions: The evidence suggests that biological therapies may reduce the risk of exacerbations in patients with chronic obstructive pulmonary disease (COPD). However, the overall impact on lung function and quality of life remains inconclusive. The variability in study outcomes, particularly concerning SGRQ scores and FEV1, emphasizes the need for continuing monitoring evidence. PROSPERO /OSF Protocol Registration DOI: 10.17605/OSF.IO/SUYD2 STRUCTURED Objective: To synthesize and update evidence on the efficacy and safety of biological therapy for chronic obstructive pulmonary disease (COPD). Methods: This living evidence synthesis included systematic reviews (SRs) and randomized controlled trials (RCTs) comparing biological therapies (e.g., benralizumab, mepolizumab, dupilumab) with placebo or standard care in adults with moderate to severe COPD. Automated searches were conducted using the Epistemonikos “Living Overview of Evidence” (L.OVE) platform, supplemented by manual searches. Two reviewers independently screened studies, extracted data, and assessed risk of bias using Cochrane RoB2 for RCTs and AMSTAR II for SRs. Meta-analyses were performed, and the certainty of evidence was evaluated using the GRADE approach. Results: Nine RCTs were included. Biological therapy probably reduces annual exacerbation rates (moderate certainty; MD -0.12, 95% CI -0.23 to 0.00). The evidence is very uncertain about its effect on quality of life (SGRQ score: MD 0.05, 95% CI -0.04 to 0.14; very low certainty) due to serious inconsistency (I² = 95.5%) and imprecision. Biological therapy may result in little to no difference in lung function (FEV1: MD 0.02, 95% CI -0.02 to 0.06; low certainty), with serious inconsistency (I² = 76.8%) and imprecision. Biological therapy probably results in no difference in total adverse events (moderate certainty; RR 1.02, 95% CI 0.99 to 1.05) but likely reduces severe adverse events (high certainty; RR 0.84, 95% CI 0.77 to 0.93). Conclusions: Current evidence suggests that biological therapies for COPD provide little to no clinical benefit over standard care in terms of exacerbation rates, lung function, or safety, with uncertain effects on quality of life. Biological therapy probably has little to no effect on annual exacerbations compared with standard care. There is likely no meaningful difference in lung function (FEV1) compared with standard care. Biologicals probably result in no difference in the number of total adverse events. Regarding the effect on quality of life, measured by the SGRQ compared with standard care, the evidence is very uncertain; therefore, no conclusions can be drawn. Overall, the certainty of the evidence supporting these statements is generally moderate, but is particularly limited by imprecision in estimates when considering thresholds for the minimal important difference (MID).
- Open Access
- 23 September 2025
- Published by Asociacion Latinoamericana de Torax in Respirar
- Vol. 17 (3) , 287-296
Nueva era en el abordaje del adenocarcinoma de pulmón estadio temprano: estudio observacional con seguimiento de 3 años
Background: Lung cancer is frequently diagnosed in advanced stages and is currently the leading cause of cancer-related mortality worldwide. A multidisciplinary approach is crucial to optimize diagnosis, treatment and improve patient survival. Methods: A retrospective cohort analytical study over two time periods, including patients over 18 years old with early-stage lung adenocarcinoma treated at a high-complexity oncology center in Colombia. The exposure group (2021-2023) received multidisciplinary care, while the non-exposure group (2018-2020) was managed conventionally by individual specialists. The study aimed to compare clinical outcomes and treatment times between both groups. Statistical analysis was based on the distribution of variables. Results: A total of 34 patients were included. The multidisciplinary approach enabled earlier diagnosis of lung adenocarcinoma, increasing early-stage identification from 30% to 61% between 2018 and 2022. Additionally, the multidisciplinary group had a higher proportion of asymptomatic cases (54% vs. 32%) and a lower relapse rate (7% vs. 52%) compared to conventional management. Treatment initiation times were significantly reduced from 3.2 to 2.2 months (p < 0.05), and the time from pathology to treatment decreased to 30 days in the multidisciplinary group versus 85 days in the conventional group. Conclusions: The multidisciplinary approach reduced waiting times for the initiation of cancer treatment, increased treatment adherence and improved clinical outcomes.
- 23 September 2025
- Published by Asociacion Latinoamericana de Torax in Respirar
- Vol. 17 (3) , 287-296
Open AccessNueva era en el abordaje del adenocarcinoma de pulmón estadio temprano: estudio observacional con seguimiento de 3 años
Background: Lung cancer is frequently diagnosed in advanced stages and is currently the leading cause of cancer-related mortality worldwide. A multidisciplinary approach is crucial to optimize diagnosis, treatment and improve patient survival. Methods: A retrospective cohort analytical study over two time periods, including patients over 18 years old with early-stage lung adenocarcinoma treated at a high-complexity oncology center in Colombia. The exposure group (2021-2023) received multidisciplinary care, while the non-exposure group (2018-2020) was managed conventionally by individual specialists. The study aimed to compare clinical outcomes and treatment times between both groups. Statistical analysis was based on the distribution of variables. Results: A total of 34 patients were included. The multidisciplinary approach enabled earlier diagnosis of lung adenocarcinoma, increasing early-stage identification from 30% to 61% between 2018 and 2022. Additionally, the multidisciplinary group had a higher proportion of asymptomatic cases (54% vs. 32%) and a lower relapse rate (7% vs. 52%) compared to conventional management. Treatment initiation times were significantly reduced from 3.2 to 2.2 months (p < 0.05), and the time from pathology to treatment decreased to 30 days in the multidisciplinary group versus 85 days in the conventional group. Conclusions: The multidisciplinary approach reduced waiting times for the initiation of cancer treatment, increased treatment adherence and improved clinical outcomes.
- 1 August 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 62 (11) , 1902-1911
Attitudes, barriers, and facilitators for the use of rescue therapy in patients with mild to moderate asthma
To explore and understand the barriers and facilitators for correctly using maintenance/controller and rescue treatments in adults with mild to moderate asthma (GINA 2020 classification) attending a reference center for asthma in Bogotá, Colombia, during the years 2021-2022. A qualitative study with a phenomenological approach using semi-structured interviews with adults with mild to moderate asthma, under a purposive non-probabilistic sampling. Data analysis was conducted using Nvivo software (Version 11.0) through: reading and re-reading, memo generation, coding, category generation, and connection between categories. Thirty-one patients were interviewed (mean age: 44.3 years) with a 1:1 male/female ratio. 77.4% with moderate asthma. Patients' experiences were grouped into three themes with 12 categories: barriers related to the individual (inadequate knowledge about maintenance inhalers, insufficient understanding of their current state due to lack of information, disagreement in treatment among non-adherent patients, and difficulties in implementation and practical application), barriers related to the healthcare system (lack of follow-up, medication availability, administrative procedures, and waiting times), and patient-related facilitators (adequate knowledge of the functioning and correct use of inhalers for treatment, proactive attitude, and motivation to receive information). Based on the identified barriers, educating patients about the pathophysiological mechanisms of asthma (inflammation and bronchodilation) and the concept of control adapted to the patient's language could facilitate the appropriate and adherent use of pharmacological therapy.
- 1 August 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 62 (11) , 1902-1911
Attitudes, barriers, and facilitators for the use of rescue therapy in patients with mild to moderate asthma
To explore and understand the barriers and facilitators for correctly using maintenance/controller and rescue treatments in adults with mild to moderate asthma (GINA 2020 classification) attending a reference center for asthma in Bogotá, Colombia, during the years 2021-2022. A qualitative study with a phenomenological approach using semi-structured interviews with adults with mild to moderate asthma, under a purposive non-probabilistic sampling. Data analysis was conducted using Nvivo software (Version 11.0) through: reading and re-reading, memo generation, coding, category generation, and connection between categories. Thirty-one patients were interviewed (mean age: 44.3 years) with a 1:1 male/female ratio. 77.4% with moderate asthma. Patients' experiences were grouped into three themes with 12 categories: barriers related to the individual (inadequate knowledge about maintenance inhalers, insufficient understanding of their current state due to lack of information, disagreement in treatment among non-adherent patients, and difficulties in implementation and practical application), barriers related to the healthcare system (lack of follow-up, medication availability, administrative procedures, and waiting times), and patient-related facilitators (adequate knowledge of the functioning and correct use of inhalers for treatment, proactive attitude, and motivation to receive information). Based on the identified barriers, educating patients about the pathophysiological mechanisms of asthma (inflammation and bronchodilation) and the concept of control adapted to the patient's language could facilitate the appropriate and adherent use of pharmacological therapy.
- Open Access
- 13 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (22) , 6820
Two-Year Experience of a Center of Excellence for the Comprehensive Management of Non-Small Cell Lung Cancer at a Fourth-Level Hospital in Bogota, Colombia: Observational Case Series Study and Retrospective Analysis
Background: This study aimed to provide a comprehensive analysis of 56 patients admitted to the Lung Cancer Clinical Care Center (C3) at Fundación Santa Fe de Bogotá (FSFB) between 2 May 2022 and 22 April 2024. The focus was on demographic characteristics, smoking history, comorbidities, lung cancer types, TNM classification, treatment modalities, and outcomes. Methods: This observational case series study reviewed medical records and included patients over 18 years with a confirmed diagnosis of non-small cell lung cancer (NSCLC). Data were collected and analyzed for demographics, comorbidities, treatment types, biomolecular profiling, and survival rates. Ethical approval was obtained, and data were anonymized. Results: The mean age was 71.8 years with a female predominance (53.6%). A history of smoking was present in 71.4% of patients. Adenocarcinoma was the most common type (75.0%), followed by squamous cell carcinoma (19.6%). At admission, the most frequent TNM stages were IA2 (17.9%) and IVA (16.1%). One-year survival was 68.8%, and 94.3% of stage I–IIIA patients underwent PET scans. Biomolecular profiling revealed 69.2% non-mutated EGFR, 90.4% ALK-negative, and various PDL-1 expression levels. Immunotherapy was received by 91.4% of patients, with Alectinib and Osimertinib being common. Grade III–IV pneumonitis occurred in 5.4% of patients. Conclusions: The study’s findings align with existing literature, highlighting significant smoking history, common adenocarcinoma, and substantial use of immunotherapy. Limitations include the observational design, small sample size, and short follow-up period, impacting the generalizability and long-term outcome assessment. Future research should address these limitations and explore longitudinal outcomes and emerging therapies.
- 13 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (22) , 6820
Open AccessTwo-Year Experience of a Center of Excellence for the Comprehensive Management of Non-Small Cell Lung Cancer at a Fourth-Level Hospital in Bogota, Colombia: Observational Case Series Study and Retrospective Analysis
Background: This study aimed to provide a comprehensive analysis of 56 patients admitted to the Lung Cancer Clinical Care Center (C3) at Fundación Santa Fe de Bogotá (FSFB) between 2 May 2022 and 22 April 2024. The focus was on demographic characteristics, smoking history, comorbidities, lung cancer types, TNM classification, treatment modalities, and outcomes. Methods: This observational case series study reviewed medical records and included patients over 18 years with a confirmed diagnosis of non-small cell lung cancer (NSCLC). Data were collected and analyzed for demographics, comorbidities, treatment types, biomolecular profiling, and survival rates. Ethical approval was obtained, and data were anonymized. Results: The mean age was 71.8 years with a female predominance (53.6%). A history of smoking was present in 71.4% of patients. Adenocarcinoma was the most common type (75.0%), followed by squamous cell carcinoma (19.6%). At admission, the most frequent TNM stages were IA2 (17.9%) and IVA (16.1%). One-year survival was 68.8%, and 94.3% of stage I–IIIA patients underwent PET scans. Biomolecular profiling revealed 69.2% non-mutated EGFR, 90.4% ALK-negative, and various PDL-1 expression levels. Immunotherapy was received by 91.4% of patients, with Alectinib and Osimertinib being common. Grade III–IV pneumonitis occurred in 5.4% of patients. Conclusions: The study’s findings align with existing literature, highlighting significant smoking history, common adenocarcinoma, and substantial use of immunotherapy. Limitations include the observational design, small sample size, and short follow-up period, impacting the generalizability and long-term outcome assessment. Future research should address these limitations and explore longitudinal outcomes and emerging therapies.
- Open Access
- 12 August 2024
- Published by Sociedad Colombiana de Anestesiologia y Reanimacion (SCARE) in Colombian Journal of Anesthesiology
- Vol. 52 (4)
Introduction to the series “GRADE in Spanish”: Basic articles about the use of evidence in clinical practice
- 12 August 2024
- Published by Sociedad Colombiana de Anestesiologia y Reanimacion (SCARE) in Colombian Journal of Anesthesiology
- Vol. 52 (4)
Open AccessIntroduction to the series “GRADE in Spanish”: Basic articles about the use of evidence in clinical practice
- Open Access
- 7 June 2024
- Published by Asociacion Colombiana de Neumologia y Cirugia de Torax in Revista Colombiana de Neumología
- Vol. 35 (2 Supl-1)
Guía de práctica clínica sobre el diagnóstico, manejo y seguimiento de la enfermedad pulmonar obstructiva crónica en Colombia 2023
Introduction: Chronic obstructive pulmonary disease (COPD) represents a significant challenge both in the economic and public health realms, both globally and within the Colombian context. This condition not only affects the patients who suffer from it, but also impacts their caregivers and the healthcare system. An increase in absenteeism has been observed both among patients and their family members, resulting in economic losses and missed employment opportunities, further exacerbating the adverse impact on the individual and their family environment. The purpose of this clinical guideline is to establish evidence-based guidelines to improve medical care and resource management in the treatment of COPD within the Colombian population. Objective: This evidence-informed clinical practice guideline (CPG) from the Asociación Colombiana de Neumología y Cirugía de Tórax (Asoneumocito), Asociación Colombiana de Medicina Interna (ACMI) y Asociación colombiana de medicina familiar (SOCMEF) y Asociación Colombiana de Fisioterapia (ASCOFI), aims to support patients, health professionals, and other actors in making decisions about diagnosis. approach, prognosis, and management of adults with COPD in the Colombian context. Materials and methods: The COPD Committee of Asoneumocito, by delegation of the presidency of the latter, formed a multidisciplinary panel of experts to balance and minimize the potential bias arising from conflicts of interest and invited the other associations that were part of this guide. The Universidad de los Andes coordinated and developed the updating or de novo of systematic reviews of the literature according to the GRADE methodology (Grading of Recommendations Assessment, Development and Evaluation). The COPD committee asked a series of questions that the expert panel prioritized, as well as outcomes according to their importance to healthcare professionals and patients. We used the Evidence-to-Decision (EtD) frameworks developed by the GRADE working group, which were subject to public comment. Results: The panel developed 10 evidence-based recommendations for the management of patients with COPD who received any of the following interventions: long-term oxygen therapy, vaccination against influenza viruses, pulmonary rehabilitation, long-acting anticholinergic inhalation therapy, triple therapy inhalation therapy, nutritional supplements, adjunctive therapy with azithromycin, smoking cessation with varenicline, and alpha-1 antitrypsin replacement. Conclusions: The recommendations included in this guide were developed for the Colombian context. The panel considered that there is a need to develop studies of economic evaluations, as well as the impact of the interventions evaluated in areas such as equity, acceptability, and feasibility of implementation in Colombia.
- 7 June 2024
- Published by Asociacion Colombiana de Neumologia y Cirugia de Torax in Revista Colombiana de Neumología
- Vol. 35 (2 Supl-1)
Open AccessGuía de práctica clínica sobre el diagnóstico, manejo y seguimiento de la enfermedad pulmonar obstructiva crónica en Colombia 2023
Introduction: Chronic obstructive pulmonary disease (COPD) represents a significant challenge both in the economic and public health realms, both globally and within the Colombian context. This condition not only affects the patients who suffer from it, but also impacts their caregivers and the healthcare system. An increase in absenteeism has been observed both among patients and their family members, resulting in economic losses and missed employment opportunities, further exacerbating the adverse impact on the individual and their family environment. The purpose of this clinical guideline is to establish evidence-based guidelines to improve medical care and resource management in the treatment of COPD within the Colombian population. Objective: This evidence-informed clinical practice guideline (CPG) from the Asociación Colombiana de Neumología y Cirugía de Tórax (Asoneumocito), Asociación Colombiana de Medicina Interna (ACMI) y Asociación colombiana de medicina familiar (SOCMEF) y Asociación Colombiana de Fisioterapia (ASCOFI), aims to support patients, health professionals, and other actors in making decisions about diagnosis. approach, prognosis, and management of adults with COPD in the Colombian context. Materials and methods: The COPD Committee of Asoneumocito, by delegation of the presidency of the latter, formed a multidisciplinary panel of experts to balance and minimize the potential bias arising from conflicts of interest and invited the other associations that were part of this guide. The Universidad de los Andes coordinated and developed the updating or de novo of systematic reviews of the literature according to the GRADE methodology (Grading of Recommendations Assessment, Development and Evaluation). The COPD committee asked a series of questions that the expert panel prioritized, as well as outcomes according to their importance to healthcare professionals and patients. We used the Evidence-to-Decision (EtD) frameworks developed by the GRADE working group, which were subject to public comment. Results: The panel developed 10 evidence-based recommendations for the management of patients with COPD who received any of the following interventions: long-term oxygen therapy, vaccination against influenza viruses, pulmonary rehabilitation, long-acting anticholinergic inhalation therapy, triple therapy inhalation therapy, nutritional supplements, adjunctive therapy with azithromycin, smoking cessation with varenicline, and alpha-1 antitrypsin replacement. Conclusions: The recommendations included in this guide were developed for the Colombian context. The panel considered that there is a need to develop studies of economic evaluations, as well as the impact of the interventions evaluated in areas such as equity, acceptability, and feasibility of implementation in Colombia.
- Open Access
- 13 May 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1321371
Blood eosinophils levels in a Colombian cohort of biomass-and tobacco-related COPD patients
Introduction: Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death among adults. In 2019, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy incorporated blood eosinophils as a biomarker to identify patients at increased risk of exacerbations which, with the history of exacerbations during the previous year, allows identification of patients who would benefit from anti-inflammatory treatment to reduce the risk of future exacerbations. The aim of this study was to describe demographic and clinical characteristics, eosinophil counts, and exacerbations in a cohort of COPD patients stratified by clinical phenotypes (non-exacerbator, frequent exacerbator, asthma-COPD overlap) in a Colombian cohort at 2600 meters above sea level.Methods: A descriptive analysis of a historical cohort of patients with a confirmed diagnosis of moderate to severe COPD (FEV1/FVC < 0.7 and at least one risk factor for COPD) from two specialized centers with comprehensive disease management programs was performed from January 2015 to March 2019. Data were extracted from medical records 1 year before and after the index date.Results: 200 patients were included (GOLD B: 156, GOLD E: 44; 2023 GOLD classification); mean age was 77.9 (SD 7.9) years; 48% were women, and 52% had biomass exposure as a COPD risk factor. The mean FEV1/FVC was 53.4% (SD 9.8), with an FEV1 of 52.7% (20.7). No differences were observed between clinical phenotypes in terms of airflow limitation. The geometric mean of absolute blood eosinophils was 197.58 (SD 2.09) cells/μL (range 0 to 3,020). Mean blood eosinophil count was higher in patients with smoking history and frequent exacerbators. At least one moderate and one severe exacerbation occurred in the previous year in 44 and 8% of patients, respectively; during the follow-up year 152 exacerbations were registered, 122 (80%) moderate and 30 (20%) severe. The highest rate of exacerbations in the follow-up year occurred in the subgroup of patients with the frequent exacerbator phenotype and eosinophils ≥300 cells/μL.Discussion: In this cohort, the frequency of biomass exposure as a risk factor is considerable. High blood eosinophil count was related to smoking, and to the frequent exacerbator phenotype.
- 13 May 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1321371
Open AccessBlood eosinophils levels in a Colombian cohort of biomass-and tobacco-related COPD patients
Introduction: Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death among adults. In 2019, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy incorporated blood eosinophils as a biomarker to identify patients at increased risk of exacerbations which, with the history of exacerbations during the previous year, allows identification of patients who would benefit from anti-inflammatory treatment to reduce the risk of future exacerbations. The aim of this study was to describe demographic and clinical characteristics, eosinophil counts, and exacerbations in a cohort of COPD patients stratified by clinical phenotypes (non-exacerbator, frequent exacerbator, asthma-COPD overlap) in a Colombian cohort at 2600 meters above sea level.Methods: A descriptive analysis of a historical cohort of patients with a confirmed diagnosis of moderate to severe COPD (FEV1/FVC < 0.7 and at least one risk factor for COPD) from two specialized centers with comprehensive disease management programs was performed from January 2015 to March 2019. Data were extracted from medical records 1 year before and after the index date.Results: 200 patients were included (GOLD B: 156, GOLD E: 44; 2023 GOLD classification); mean age was 77.9 (SD 7.9) years; 48% were women, and 52% had biomass exposure as a COPD risk factor. The mean FEV1/FVC was 53.4% (SD 9.8), with an FEV1 of 52.7% (20.7). No differences were observed between clinical phenotypes in terms of airflow limitation. The geometric mean of absolute blood eosinophils was 197.58 (SD 2.09) cells/μL (range 0 to 3,020). Mean blood eosinophil count was higher in patients with smoking history and frequent exacerbators. At least one moderate and one severe exacerbation occurred in the previous year in 44 and 8% of patients, respectively; during the follow-up year 152 exacerbations were registered, 122 (80%) moderate and 30 (20%) severe. The highest rate of exacerbations in the follow-up year occurred in the subgroup of patients with the frequent exacerbator phenotype and eosinophils ≥300 cells/μL.Discussion: In this cohort, the frequency of biomass exposure as a risk factor is considerable. High blood eosinophil count was related to smoking, and to the frequent exacerbator phenotype.